查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1856398

按产品类型、技术、剂型、药物类别和最终用户分類的药物-器材组合产品市场－2025-2032年全球预测

Drug-Device Combination Products Market by Product Type, Technology, Dosage Form, Therapeutic Class, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，药物器材组合产品市场将成长至 2,746.1 亿美元，复合年增长率为 8.34%。

关键市场统计数据
基准年 2024 1445.9亿美元
预计年份：2025年 1564.6亿美元
预测年份 2032 2746.1亿美元
复合年增长率 (%) 8.34%

一种针对联合治疗的综合方法，旨在解决现代研发生命週期中的临床创新、监管细则和商业化需求。

药理学与器材工程的整合已发展成为医疗创新和医疗服务交会点的关键领域。药物-器械组合产品将活性药物成分与工程化的递送系统结合，以增强疗效、提高患者依从性并实现新型治疗模式。本文描绘了一个多维度的图景，其中科学进步、以用户为中心的设计以及监管环境相互交融，为製造商、临床医生和支付方带来了机会和挑战。

近年来，医疗服务平台的发展趋势已从渐进式改进转向系统级解决方案，将感测器、连接性和数据分析技术融入其中。因此，研发团队必须整合製剂科学、材料工程、软体开发、人因工程、品质体係等方面的专业知识。同时，监管机构也在调整策略，开始考虑混合产品的特性，强调对器械和药物成分的安全性和有效性进行论证，并製定针对组合产品独特风险的上市后监测策略。

从商业化角度来看，支付方和采购管道越来越关注实际疗效及其对整体医疗成本的影响，因此，当临床和经济价值得到明确证实时，产品就能加速推广应用。因此，製造商发现，儘早协调临床开发、监管策略和上市计划至关重要。本引言为深入分析变革性转变、关税驱动的供应链影响、细分市场的细微差别、区域动态以及领导者可以采取的切实可行的步骤奠定了基础，从而在这个快速发展的领域取得成功。

融合技术、完善的监管以及不断变化的医疗服务预期如何重新定义联合治疗的开发方法和商业化策略

药物-器材组合产品的格局正受到技术、监管和医疗服务模式等多面向因素的共同影响而重塑，这些因素共同推动着改变。智慧型设备功能的进步，例如内建感测器、自动化给药机制和数位监测，正在催生新的依从性管理和远端医疗监测模式。这些技术进步正推动着医疗服务模式从单一产品转向整合式医疗生态系统，在这个生态系统中，设备和软体透过数据主导的洞察创造价值。

监管机构正积极回应，推出更完善的指导方针，涵盖混合产品评估、网路安全预期和上市后资料收集等方面，从而提高了整合验证和生命週期管理的标准。同时，製造商正积极探索模组化设计理念和平台化方法，以加快迭代速度并应对复杂的监管环境。供应链韧性和生产弹性已成为策略重点，推动企业增加对近岸外包、多源采购和流程自动化的投资，以最大限度地减少中断并保障产品上市时间。

临床医生和患者的期望也在不断变化，以使用者为中心的设计、简化的管理以及患者疗效的显着改善是推动产品普及的核心因素。支付者越来越要求提供成本效益和实际效用的证据，促使製造商在研发早期阶段就纳入卫生经济学和疗效研究。因此，最成功的企业往往是那些研发、监管、商业和生产部门共用基于数据的价值提案，从而支持可扩展且永续的联合治疗部署的企业。

评估2025年贸易和关税变化对筹资策略、製造本地化选择以及联合治疗供应链韧性的下游影响

2025年推出的关税政策变化和贸易措施的累积影响，对组合药物相关人员的采购、生产和分销策略产生了重大影响。关键成分、原料和成品的关税调整提高了全球价值链的成本可见性，迫使企业重新评估筹资策略和供应商合约条款。为此，许多企业加快了多元化进程，寻找替代供应商，减少单一来源依赖，并签订双重采购协议以维持供应的连续性。

除了直接投入成本外，关税还影响关键製造活动的地理位置选择以及对本地组装和生产线末端製造的投资决策。此类转移通常需要仔细分析不同司法管辖区的监管合规性，因为生产转移可能涉及新的註册、检验和品质系统义务。因此，企业一直在权衡前置作业时间的成本影响与在新地区建立合规生产所需的监管复杂性和准备时间。

重要的是，关税带来的压力促使采购、监管和产品团队加强合作，以确保采购调整不会影响材料的兼容性、设备性能或药物稳定性。产业因应措施包括重新谈判供应商合约以纳入紧急条款、扩大合约避险策略的使用，以及有针对性地投资供应链视觉技术。总而言之，这些因应措施体现了在适应不断变化的贸易环境的同时，为维护产品完整性和市场进入的务实努力。

从产品类型、实行技术、剂型、治疗层级和最终用户环境等因素出发的细分观点，指南策略优先排序。

细緻的市场细分框架揭示了产品、技术、剂型、治疗重点和终端用户背景如何影响组合药物市场的策略和创新重点。基于产品类型，该市场细分为药物释放型支架、吸入器、注射系统、预填充式注射器和注射笔、外用药物和经皮贴片。注射系统类别进一步细分为自动注射器和无针注射器，每种注射器都面临不同的工程和使用者介面挑战。这种产品层面的差异化影响着监管路径、包装要求和临床医生培训需求，也决定了在不影响药物稳定性的前提下，数位化功能在设备中的应用程度。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩展穿戴式药物输送贴片的功能，并整合数位监测功能
  • 远距呼吸治疗依从性追踪中互联吸入装置的采用率不断提高
  • 全球监管协调努力加速了组合药物的核准。
  • 将人工智慧整合到设备端诊断中，以实现个人化给药优化
  • 开发用于标靶治疗回馈的可生物降解药物释放型微感测器
  • 以使用者为中心的智慧注射笔设计理念的出现，旨在改善患者的自我注射体验。
  • 生技公司与医疗器材製造商合作，共同开发新型生物製药递送系统

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的药物-器材组合产品市场

  • 药物释放型支架
  • 吸入器
  • 注射器系统
    • 自动注射器
    • 无针注射器
  • 预填充式注射器和注射笔
  • 外用药物
  • 经皮贴剂

9. 按技术分類的药物-器材组合产品市场

  • 先进排放技术
  • 可生物降解技术
  • 传统设备 - 药物技术
  • 智慧型装置技术
    • 自动加药
    • 数位监控

10. 按剂型分類的药物-器材组合产品市场

  • 液体剂型
  • 半固态剂型
    • 奶油
    • 软膏
    • 粉末
  • 固态剂型
    • 胶囊
    • 药片

11. 按治疗层级的药物-器械组合产品市场

  • 心血管药物
  • 糖尿病/内分泌
  • 荷尔蒙补充疗法
  • 癌症治疗药物
    • 化疗
    • 参与式肿瘤护理
  • 疼痛管理

12. 按最终用户分類的药物-器械组合产品市场

  • 门诊手术中心
  • 居家照护环境
  • 医院和诊所
  • 专科诊所

13. 按地区分類的药物-器材组合产品市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 按类别分類的药物-器材组合产品市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国药物-器材组合产品市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • AbbVie Inc.
    • B. Braun SE
    • Baxter International Inc.
    • Becton, Dickinson and Company
    • BIOTRONIK SE & Co. KG
    • Boston Scientific Corporation
    • Braile Biomedica
    • Cardinal Health, Inc.
    • CODAN Companies
    • Cook Group Incorporated
    • F. Hoffmann-La Roche Ltd.
    • Fresenius Kabi
    • ICU Medical, Inc.
    • InSitu Technologies Inc.
    • JMS North America Corporation
    • Lepu Medical Technology Company
    • Medtronic PLC
    • MicroPort Scientific Corporation
    • Novartis AG
    • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • SOOIL Developments Co., Ltd.
    • Stryker Corporation
    • Teleflex Incorporated
    • Terumo Group
    • Viatris Inc.
    • WL Gore & Associates Inc.
Product Code: MRR-742BD517D8D5

The Drug-Device Combination Products Market is projected to grow by USD 274.61 billion at a CAGR of 8.34% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 144.59 billion
Estimated Year [2025] USD 156.46 billion
Forecast Year [2032] USD 274.61 billion
CAGR (%) 8.34%

A comprehensive orientation to combination therapeutics that situates clinical innovation, regulatory nuance, and commercialization imperatives within a modern development lifecycle

The integration of pharmacology and device engineering has evolved into a defining discipline at the intersection of medical innovation and healthcare delivery. Drug-device combination products bring together active pharmaceutical ingredients and engineered delivery systems to enhance therapeutic performance, improve adherence, and enable new modes of care. This introduction frames a multidimensional landscape in which scientific advances, user-centered design, and regulatory expectations converge to create both opportunity and complexity for manufacturers, clinicians, and payers.

Recent years have seen a shift from incremental enhancements toward systems-level solutions that embed sensors, connectivity, and data analytics into delivery platforms. Consequently, development teams must orchestrate expertise spanning formulation science, materials engineering, software development, human factors, and quality systems. At the same time, regulatory pathways have adapted to account for hybrid product characteristics, emphasizing demonstration of safety and efficacy across both device and drug components, as well as post-market surveillance strategies tailored to combination-specific risks.

From a commercialization perspective, payers and procurement channels are increasingly focused on real-world performance and total cost of care implications, which can accelerate adoption where clinical and economic value are clearly demonstrated. Manufacturers therefore find that early alignment between clinical development, regulatory strategy, and market access planning is essential. This introduction sets the stage for a deeper analysis of transformative shifts, tariff-driven supply chain impacts, segmentation nuances, regional dynamics, and actionable steps leaders can take to succeed in this rapidly evolving domain.

How converging technology, regulatory refinement, and shifting care delivery expectations are redefining development approaches and commercialization strategies in combination therapeutics

The landscape for drug-device combination products is being reshaped by a confluence of technological, regulatory, and care-delivery forces that together are driving transformative change. Advances in smart device capabilities-such as embedded sensors, automatic dosing mechanisms, and digital monitoring-are enabling new models of adherence management and remote therapeutic monitoring. These technological enhancements are fostering a move from discrete product offerings toward integrated care ecosystems in which devices and software generate value through data-driven insights.

Regulatory authorities are responding by refining guidance that addresses hybrid product evaluation, cybersecurity expectations, and post-market data collection, thereby elevating the bar for integrated validation and lifecycle management. Concurrently, manufacturers are pursuing modular design philosophies and platform approaches to accelerate iteration while managing regulatory complexity. Supply chain resilience and manufacturing flexibility have become strategic priorities, prompting investments in nearshoring, multi-sourcing, and process automation to minimize disruption and protect time-to-market.

Clinician and patient expectations are also evolving: user-centric design, simplified administration, and demonstrable improvements in patient outcomes are central to adoption. Payers increasingly demand evidence of cost-effectiveness and real-world utility, which incentivizes manufacturers to incorporate health economics and outcomes research earlier in development. As a result, the most successful organizations are those that align R&D, regulatory, commercial, and manufacturing functions around a shared, data-informed value proposition that supports scalable, sustainable deployment of combination therapies.

Evaluating the downstream consequences of 2025 trade and tariff shifts on sourcing strategies, manufacturing localization choices, and supply chain resilience for combination therapies

The cumulative impact of tariff policy changes and trade measures introduced in 2025 has had meaningful implications for the procurement, manufacturing, and distribution strategies of combination product stakeholders. Tariff adjustments on critical components, raw materials, and finished goods have heightened cost visibility across global value chains, prompting companies to reassess sourcing strategies and contractual terms with suppliers. In response, many organizations accelerated diversification efforts, identifying alternate suppliers and dual-sourcing arrangements to mitigate single-origin exposure and maintain continuity of supply.

Beyond direct input costs, tariffs have influenced decisions around geographic placement of critical manufacturing activities and investment in localized assembly or final-stage manufacturing. These shifts are often accompanied by careful analysis of regulatory compliance across jurisdictions, given that relocating production can entail new registration, inspection, and quality system obligations. Firms have therefore balanced the cost impact of tariffs against the regulatory complexity and lead time associated with establishing compliant manufacturing in new regions.

Importantly, tariff-driven pressures have incentivized tighter collaboration across procurement, regulatory, and product teams to ensure that adjustments in sourcing do not compromise material compatibility, device performance, or drug stability. Industry response has included renegotiated supplier agreements with built-in contingency clauses, expanded use of contractual hedging strategies, and targeted investments in supply chain visibility technologies. Taken together, these responses reflect a pragmatic effort to preserve product integrity and market access while adapting to an altered trade environment.

An integrated segmentation perspective connecting product types, enabling technologies, dosage forms, therapeutic classes, and end-user environments to guide strategic prioritization

A nuanced segmentation framework illuminates how product, technology, dosage form, therapeutic focus, and end-user context shape strategy and innovation priorities across the combination product landscape. Based on Product Type, the market is studied across Drug-Eluting Stents, Inhalers, Injector Systems, Prefilled Syringes & Pens, Topical Medicines, and Transdermal Patches; the Injector Systems category is further examined across Auto-Injectors and Needle-Free Injectors, each presenting different engineering and user-interface challenges. This product-level differentiation influences regulatory pathways, packaging requirements, and clinician training needs, and it also determines the extent to which devices can incorporate digital features without disrupting drug stability.

Based on Technology, the market is studied across Advanced Release Technologies, Biodegradable Technology, Conventional Device-Drug Technology, and Smart Device Technologies; the Smart Device Technologies subgroup is further analyzed for Automatic Dosing and Digital Monitoring capabilities. Adoption of advanced release and biodegradable platforms often hinges on material science innovations and compatibility testing, while smart technologies demand robust software verification, cybersecurity measures, and data interoperability strategies to support clinical workflows and reimbursement claims.

Based on Dosage Form, the market is studied across Liquid Dosage Forms, Semi-Solid Dosage Forms, and Solid Dosage Forms; the Semi-Solid Dosage Forms are further explored through Creams, Ointments, and Powders, and the Solid Dosage Forms are further considered across Capsules and Tablets. Dosage form selection affects stability, device design, and patient administration protocols, and it imposes specific analytical and quality control requirements. Based on Therapeutic Class, the market is studied across Cardiovascular Medications, Diabetes & Endocrinology, Hormonal Replacement Therapy, Oncology Drugs, and Pain Management; the Oncology Drugs subset is further categorized into Chemotherapy and Participatory Oncology Treatment, reflecting divergent safety profiles and monitoring needs. Finally, Based on End-User, the market is studied across Ambulatory Surgical Centers, Homecare Settings, Hospitals and Clinics, and Specialty Clinics, which together define differing operational constraints, training resources, and procurement models. Integrating these segmentation dimensions helps stakeholders prioritize product design trade-offs, regulatory strategy, and market access efforts according to the technical, clinical, and delivery-context nuances that matter most.

How divergent regulatory regimes, procurement behaviors, and manufacturing priorities across major regions shape development and commercialization strategies for combination therapeutics

Regional dynamics continue to exert strong influence over regulatory expectations, manufacturing strategies, and commercial deployment of combination products, with distinct patterns emerging across major geographies. In the Americas, regulatory frameworks are increasingly harmonized around risk-based evaluation and post-market surveillance expectations, while purchaser institutions emphasize clinical evidence and supply chain visibility. These conditions favor solutions that demonstrate measurable improvements in adherence and outcomes, and they support commercial models that pair product deployment with services such as training and remote monitoring.

Across Europe, Middle East & Africa, diverse regulatory regimes and procurement modalities require adaptive market access strategies that account for national reimbursement mechanisms and localized clinical guidelines. In this complex environment, manufacturers often prioritize region-specific regulatory expertise and targeted pilot programs to establish clinical value and payer acceptance. Moreover, the emphasis on sustainability and circular economy principles in parts of this region can influence material selection and end-of-life planning for device components.

The Asia-Pacific region presents a combination of rapid adoption potential and heterogeneity in regulatory maturity. Several markets in this region are expediting approvals for innovative delivery platforms while simultaneously building local manufacturing capability. These dynamics make Asia-Pacific attractive for companies seeking scale and cost efficiencies, but they also demand careful navigation of intellectual property protection, localization requirements, and partnership models with local distributors and contract manufacturers. Taken together, regional insights underscore the importance of tailoring regulatory, manufacturing, and commercial strategies to local realities while maintaining global standards for quality and evidence generation.

How collaborative alliances, platform investments, and capability expansion among manufacturers, suppliers, and service providers are redefining competitive advantage in combination product ecosystems

Competitive behavior among product developers, suppliers, and service providers is characterized by a blend of platform innovation, strategic partnerships, and capability-building investments. Established pharmaceutical firms and device manufacturers are increasingly entering into collaborative arrangements to combine formulation expertise with device engineering, often structuring alliances to align incentives around clinical outcomes and shared commercial goals. At the same time, specialized medtech companies and technology startups focus on niche capabilities-such as sensor integration, injection mechanism miniaturization, or wearable adhesion systems-that can be licensed or acquired to complete broader product portfolios.

Supply chain and manufacturing players are differentiating through investments in scalable, compliant assembly capabilities and quality management systems tailored for combination products. Contract development and manufacturing organizations are expanding service offerings to include integrated testing, stability programs, and human factors engineering support to reduce time-to-market for sponsors. Additionally, software vendors and digital health specialists are forging relationships with device and drug developers to provide data platforms, analytics, and interoperability solutions that support remote monitoring and adherence programs.

Regulatory consultants and clinical research organizations are also adapting, offering end-to-end support for regulatory strategy, clinical validation, and post-market evidence generation specific to hybrid product requirements. Across this ecosystem, successful companies demonstrate a capacity to manage complex multidisciplinary programs, deploy capital selectively to bridge capability gaps, and structure commercial models that highlight demonstrable improvements in patient outcomes and system-level efficiencies.

Practical cross-functional strategies and tactical investments that enable organizations to reduce development risk, strengthen adoption pathways, and sustain competitive differentiation

Industry leaders seeking to translate innovation into sustained market success should pursue a set of coordinated, actionable strategies that align scientific, regulatory, manufacturing, and commercial functions. First, embed cross-functional governance early in development to reconcile formulation requirements with device engineering, human factors, and software validation needs. This integrated governance model reduces rework, enables clearer regulatory submissions, and accelerates alignment on clinical endpoints that matter to payers and clinicians.

Second, prioritize supply chain resilience by diversifying critical component sourcing and investing in visibility tools that track provenance and quality attributes. Where feasible, evaluate nearshoring or flexible manufacturing arrangements for final assembly to shorten lead times and simplify regulatory logistics. Third, incorporate digital features and data strategies that augment therapeutic value while ensuring robust cybersecurity, privacy compliance, and interoperability with existing clinical systems. Early engagement with regulators on digital elements can clarify expectations and reduce downstream uncertainty.

Fourth, adopt value-based evidence generation approaches that combine clinical trials with pragmatic, real-world outcome studies to demonstrate both clinical efficacy and economic impact. Align commercial models accordingly, offering bundled solutions that pair product access with training, support services, and data-driven programs to improve adherence. Finally, cultivate strategic partnerships and targeted M&A to fill capability gaps rather than trying to internalize every technical domain. By focusing on these priorities, leaders can reduce development risk, enhance adoption, and create defensible value propositions in an increasingly integrated therapeutic environment.

A transparent mixed-methods research approach combining expert interviews, targeted secondary analysis, and triangulation to validate insights while acknowledging methodological limitations

The research behind this analysis combines qualitative and quantitative methods designed to surface actionable insights while maintaining methodological rigor. Primary inputs included structured interviews with cross-disciplinary subject-matter experts, including clinical practitioners, regulatory specialists, procurement leaders, and manufacturing engineers, which provided real-world perspectives on operational constraints and adoption drivers. These interviews were supplemented by targeted expert panels to validate emergent themes and test the applicability of strategic recommendations across different product types and regions.

Secondary research drew on peer-reviewed literature, regulatory guidance documents, standards publications, and company disclosures to build a factual baseline around technical capabilities, safety considerations, and policy trends. Data triangulation techniques were applied to reconcile differing viewpoints and to ensure that conclusions reflect convergent evidence rather than isolated observations. Where appropriate, case studies of recent product launches and regulatory decisions were analyzed to extract lessons on go-to-market sequencing, evidence generation, and post-market surveillance.

Quality assurance procedures included independent review by methodological peers, consistency checks across data sources, and sensitivity analysis to identify areas of uncertainty. Limitations of the approach are acknowledged, particularly regarding rapidly evolving technology domains and jurisdiction-specific regulatory actions that may change after the analysis period. To mitigate these limitations, readers are encouraged to supplement the findings with contemporaneous regulatory updates and localized expert input when applying the recommendations to specific program decisions.

A succinct synthesis emphasizing integrated development, supply chain agility, and evidence-based commercialization as the core imperatives for combination therapy success

In conclusion, drug-device combination products occupy a dynamic and strategically important space in modern healthcare, offering the potential to improve therapeutic efficacy, patient adherence, and system-level outcomes. The most consequential shifts are occurring at the intersection of technology integration, regulatory adaptation, and changing care-delivery norms. Success in this environment requires manufacturers to adopt integrated development models, to invest in supply chain flexibility, and to prioritize evidence generation that demonstrates both clinical and economic value.

Stakeholders must also navigate the operational realities introduced by recent trade measures and evolving regional requirements, aligning sourcing and manufacturing choices with regulatory readiness and commercial objectives. Market participants who proactively design for regulatory compliance, user-centered deployment, and robust post-market data collection will be better positioned to secure adoption among clinicians and payers. Collaboration across the ecosystem-linking specialized technology providers, contract manufacturers, clinical networks, and reimbursement experts-remains a central enabler for accelerating innovation while managing risk.

Ultimately, informed decision-making grounded in multidisciplinary evidence and adaptive strategy will determine which organizations translate scientific advances into widely adopted combination therapies. The themes explored in this summary point to a pragmatic path forward: integrate capabilities early, validate value rigorously, and structure commercial models that deliver measurable benefits to patients and healthcare systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of wearable drug delivery patches with integrated digital monitoring capabilities
  • 5.2. Rising adoption of connected inhaler devices for remote respiratory therapy adherence tracking
  • 5.3. Regulatory harmonization efforts accelerating approvals for combination product submissions globally
  • 5.4. Integration of artificial intelligence in on-device diagnostics for personalized dosing optimization
  • 5.5. Development of biodegradable implantable drug-eluting microsensors for targeted therapy feedback
  • 5.6. Emergence of user-centered design in smart injection pens to improve patient self-administration
  • 5.7. Collaborative partnerships between biotech firms and device manufacturers to co-develop novel biologic delivery systems

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug-Device Combination Products Market, by Product Type

  • 8.1. Drug-Eluting Stents
  • 8.2. Inhalers
  • 8.3. Injector Systems
    • 8.3.1. Auto-Injectors
    • 8.3.2. Needle-Free Injectors
  • 8.4. Prefilled Syringes & Pens
  • 8.5. Topical Medicines
  • 8.6. Transdermal Patches

9. Drug-Device Combination Products Market, by Technology

  • 9.1. Advanced Release Technologies
  • 9.2. Biodegradable Technology
  • 9.3. Conventional Device-Drug Technology
  • 9.4. Smart Device Technologies
    • 9.4.1. Automatic Dosing
    • 9.4.2. Digital Monitoring

10. Drug-Device Combination Products Market, by Dosage Form

  • 10.1. Liquid Dosage Forms
  • 10.2. Semi-Solid Dosage Forms
    • 10.2.1. Creams
    • 10.2.2. Ointments
    • 10.2.3. Powders
  • 10.3. Solid Dosage Forms
    • 10.3.1. Capsules
    • 10.3.2. Tablets

11. Drug-Device Combination Products Market, by Therapeutic Class

  • 11.1. Cardiovascular Medications
  • 11.2. Diabetes & Endocrinology
  • 11.3. Hormonal Replacement Therapy
  • 11.4. Oncology Drugs
    • 11.4.1. Chemotherapy
    • 11.4.2. Participatory Oncology Treatment
  • 11.5. Pain Management

12. Drug-Device Combination Products Market, by End-User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Homecare Settings
  • 12.3. Hospitals and Clinics
  • 12.4. Specialty Clinics

13. Drug-Device Combination Products Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drug-Device Combination Products Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug-Device Combination Products Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. AbbVie Inc.
    • 16.3.3. B. Braun SE
    • 16.3.4. Baxter International Inc.
    • 16.3.5. Becton, Dickinson and Company
    • 16.3.6. BIOTRONIK SE & Co. KG
    • 16.3.7. Boston Scientific Corporation
    • 16.3.8. Braile Biomedica
    • 16.3.9. Cardinal Health, Inc.
    • 16.3.10. CODAN Companies
    • 16.3.11. Cook Group Incorporated
    • 16.3.12. F. Hoffmann-La Roche Ltd.
    • 16.3.13. Fresenius Kabi
    • 16.3.14. ICU Medical, Inc.
    • 16.3.15. InSitu Technologies Inc.
    • 16.3.16. JMS North America Corporation
    • 16.3.17. Lepu Medical Technology Company
    • 16.3.18. Medtronic PLC
    • 16.3.19. MicroPort Scientific Corporation
    • 16.3.20. Novartis AG
    • 16.3.21. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • 16.3.22. SOOIL Developments Co., Ltd.
    • 16.3.23. Stryker Corporation
    • 16.3.24. Teleflex Incorporated
    • 16.3.25. Terumo Group
    • 16.3.26. Viatris Inc.
    • 16.3.27. W. L. Gore & Associates Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DRUG-DEVICE COMBINATION PRODUCTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DRUG-DEVICE COMBINATION PRODUCTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRUG-DEVICE COMBINATION PRODUCTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DRUG-ELUTING STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DRUG-ELUTING STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DRUG-ELUTING STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DRUG-ELUTING STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DRUG-ELUTING STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DRUG-ELUTING STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTO-INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTO-INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTO-INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTO-INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PREFILLED SYRINGES & PENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PREFILLED SYRINGES & PENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PREFILLED SYRINGES & PENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PREFILLED SYRINGES & PENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PREFILLED SYRINGES & PENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PREFILLED SYRINGES & PENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TOPICAL MEDICINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TOPICAL MEDICINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TOPICAL MEDICINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TOPICAL MEDICINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TOPICAL MEDICINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TOPICAL MEDICINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TRANSDERMAL PATCHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TRANSDERMAL PATCHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TRANSDERMAL PATCHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TRANSDERMAL PATCHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ADVANCED RELEASE TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ADVANCED RELEASE TECHNOLOGIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ADVANCED RELEASE TECHNOLOGIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ADVANCED RELEASE TECHNOLOGIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ADVANCED RELEASE TECHNOLOGIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ADVANCED RELEASE TECHNOLOGIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY BIODEGRADABLE TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY BIODEGRADABLE TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY BIODEGRADABLE TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY BIODEGRADABLE TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY BIODEGRADABLE TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY BIODEGRADABLE TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CONVENTIONAL DEVICE-DRUG TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CONVENTIONAL DEVICE-DRUG TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CONVENTIONAL DEVICE-DRUG TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CONVENTIONAL DEVICE-DRUG TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CONVENTIONAL DEVICE-DRUG TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CONVENTIONAL DEVICE-DRUG TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTOMATIC DOSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTOMATIC DOSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTOMATIC DOSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTOMATIC DOSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTOMATIC DOSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTOMATIC DOSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIGITAL MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIGITAL MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIGITAL MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIGITAL MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIGITAL MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIGITAL MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CARDIOVASCULAR MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CARDIOVASCULAR MEDICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CARDIOVASCULAR MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CARDIOVASCULAR MEDICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CARDIOVASCULAR MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CARDIOVASCULAR MEDICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIABETES & ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIABETES & ENDOCRINOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIABETES & ENDOCRINOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIABETES & ENDOCRINOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIABETES & ENDOCRINOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIABETES & ENDOCRINOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HORMONAL REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HORMONAL REPLACEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HORMONAL REPLACEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HORMONAL REPLACEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HORMONAL REPLACEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HORMONAL REPLACEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PARTICIPATORY ONCOLOGY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PARTICIPATORY ONCOLOGY TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PARTICIPATORY ONCOLOGY TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PARTICIPATORY ONCOLOGY TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PARTICIPATORY ONCOLOGY TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PARTICIPATORY ONCOLOGY TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEV